🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hanrong Feng

ORCID: 0000-0002-2133-5374
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma”.

A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2005
N/A
0.503DataRank · unranked
14 citations

Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S. Kapner, Bose Kochupurakkal +23 more

REV7/FANCV Binds to CHAMP1 and Promotes Homologous Recombination Repair

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.04.463067
N/A
0DataRank · unranked
1 citations

Prabha Sarangi, Hanrong Feng, Lisa A. Moreau, Huy Nguyen, Connor S. Clairmont +2 more

REV7/FANCV Binds to CAMP and Promotes Homologous Recombination Repair

Research Square(2021)10.21203/rs.3.rs-757230/v1
N/A
0DataRank · unranked
0 citations

Prabha Sarangi, Hanrong Feng, Lisa A. Moreau, Huy Nguyen, Connor S. Clairmont +2 more

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0177
N/A
0DataRank · unranked
243 citations

Megan T. Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso, Brendan D. Parent +50 more